



## **Haleon plc: Update on off-market purchase alongside Pfizer Inc. offering**

**19 March 2025:** Further to its announcement on 18 March 2025, Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) has agreed to make an off-market purchase of 44,155,844 ordinary shares of £0.01 each of the Company from Pfizer Inc. ("Pfizer") pursuant to the terms of the share purchase deed entered into between Haleon and Pfizer that was previously approved by Haleon's shareholders.

The off-market purchase is being made in conjunction with, and subject to the completion of an offering by Pfizer to institutional investors, the results of which have been announced by Pfizer today. The purchase price payable by Haleon to Pfizer for the off-market purchase is £3.85 per ordinary share and the total consideration payable will be approximately £170 million.

The off-market purchase represents a portion of the £500 million allocated to share buybacks in 2025 announced on 27 February 2025. The purchased ordinary shares will be cancelled.

On completion of the off-market purchase and Pfizer's offering to institutional investors, Pfizer's interest in Haleon's issued ordinary shares with voting rights is expected to reduce from approximately 7.3% to nil.

**Brian McNamara, Chief Executive Officer of Haleon commented:** "Today's transaction is an important milestone for the business and marks Pfizer fully exiting its stake in Haleon, having been at 32% at the time of demerger in July 2022. Our participation in the offering is consistent with our disciplined capital allocation priorities, and supports our commitment to deliver attractive returns for shareholders, underpinned by a strong investment grade balance sheet. Nearly three years on from demerger, Haleon is in a position of strength and is well placed to capitalise on the significant opportunities ahead."

The Company will make a further announcement upon completion of the off-market purchase.

**Amanda Mellor**  
**Company Secretary**

### **Enquiries**

#### **Investors**

Jo Russell +44 7787 392441  
Rakesh Patel +44 7552 484646  
Emma White +44 7823 523562

Email: [investor-relations@haleon.com](mailto:investor-relations@haleon.com)

#### **Media**

Zoë Bird +44 7736 746167  
Victoria Durman +44 7894 505730

Email: [corporate.media@haleon.com](mailto:corporate.media@haleon.com)

### **About Haleon**

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information please visit [www.haleon.com](http://www.haleon.com)

For more information please visit [www.naleon.com](http://www.naleon.com)

Not for release, publication or distribution in the United States, Canada, Japan, Australia or any other state or jurisdiction in which such release, publication or distribution would be unlawful.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDGLGDXUXBDGUC